Hostname: page-component-78c5997874-fbnjt Total loading time: 0 Render date: 2024-11-11T04:09:29.909Z Has data issue: false hasContentIssue false
  • English
  • Français

Extracting a needle from a haystack: reanalysis of whole genome data reveals a readily translatable finding

Published online by Cambridge University Press:  12 February 2009

R. Keers ,
A. E. Farmer  and
K. J. Aitchison
R. Keers*
Affiliation:
MRC SGDP Centre, Institute of Psychiatry at King's College London, London, UK
A. E. Farmer
Affiliation:
MRC SGDP Centre, Institute of Psychiatry at King's College London, London, UK
K. J. Aitchison
Affiliation:
MRC SGDP Centre, Institute of Psychiatry at King's College London, London, UK
*
*Address for correspondence: R. Keers, MRC SGDP Centre, Institute of Psychiatry, 16 De Crespigny Park, Denmark Hill, LondonSE5 8AF, UK. (Email: robert.keers@iop.kcl.ac.uk)
Get access Rights & Permissions [Opens in a new window]

Abstract

There is significant unmet need for more effective treatments for bipolar disorder. The drug discovery process is becoming prohibitively expensive. Hence, biomarker clues to assist or shortcut this process are now widely sought. Using the publicly available data from the whole genome association study conducted by the Wellcome Trust Case Control Consortium, we sought to identify groups of genetic markers (single nucleotide polymorphisms) in which each marker was independently associated with bipolar disorder, with a less stringent threshold than that set by the original investigators (p⩽1×10−4). We identified a group of markers occurring within the CACNA1C gene (encoding the alpha subunit of the calcium channel Cav1.2). We then ascertained that this locus had been previously associated with the disorder in both a smaller and a whole genome study, and that a number of drugs blocking this channel (including verapamil and diltiazem) had been trialled in the treatment of bipolar disorder. The dihydropyridine-based blockers such as nimodipine that bind specifically to Cav1.2 and are more penetrant to the central nervous system have shown some promising early results; however, further trials are indicated. In addition, migraine is commonly seen in affective disorder, and calcium channel antagonists are successfully used in the treatment of migraine. One such agent, flunarizine, is structurally related to other first-generation derivatives of antihistamines such as antipsychotics. This implies that flunarizine could be useful in the treatment of bipolar disorder, and, furthermore, that other currently licensed drugs should be investigated for antagonism of Cav1.2.

Keywords

bipolar disorderCACNA1CCav1.2calcium channel blockersdihydropyridinegenetic predisposition to disease
Type
Invited Review
Information
Psychological Medicine , Volume 39 , Issue 8 , August 2009 , pp. 1231 - 1235
Copyright
Copyright © 2009 Cambridge University Press

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Amery, WK (1983). Flunarizine, a calcium channel blocker: a new prophylactic drug in migraine. Headache 23, 70–74.CrossRefGoogle ScholarPubMed
Baum, AE, Akula, N, Cabanero, M, Cardona, I, Corona, W, Klemens, B, Schulze, TG, Cichon, S, Rietschel, M, Nothen, MM, Georgi, A, Schumacher, J, Schwarz, M, Abou, JR, Hofels, S, Propping, P, Satagopan, J, tera-Wadleigh, SD, Hardy, J, McMahon, FJ (2008). A genome-wide association study implicates diacylglycerol kinase eta (DGKH) and several other genes in the etiology of bipolar disorder. Molecular Psychiatry 13, 197–207.CrossRefGoogle ScholarPubMed
Brunet, G, Cerlich, B, Robert, P, Dumas, S, Souetre, E, Darcourt, G (1990). Open trial of a calcium-antagonist, nimodipine, in acute mania. Clinical Neuropharmacology 13, 224–228.CrossRefGoogle ScholarPubMed
De Beaurepaire, R (1992). Treatment of neuroleptic-resistant mania and schizoaffective disorders. American Journal Psychiatry 149, 1614–1615.Google ScholarPubMed
Detera-Wadleigh, SD, Barden, N, Craddock, N, Ewald, H, Foroud, T, Kelsoe, J, McQuillin, A (1999). Chromosomes 12 and 16 workshop. American Journal of Medical Genetics 88, 255–259.3.0.CO;2-V>CrossRefGoogle ScholarPubMed
DiMasi, JA, Hansen, RW, Grabowski, HG (2003). The price of innovation: new estimates of drug development costs. Journal of Health Economics 22, 151–185.CrossRefGoogle Scholar
Dubovsky, SL, Thomas, M, Hijazi, A, Murphy, J (1994). Intracellular calcium signaling in peripheral cells of patients with bipolar affective-disorder. European Archives of Psychiatry and Clinical Neuroscience 243, 229–234.CrossRefGoogle Scholar
Ettinger, AB, Reed, ML, Goldberg, JF, Hirschfeld, RMA (2005). Prevalence of bipolar symptoms in epilepsy vs other chronic health disorders. Neurology 65, 535–540.CrossRefGoogle ScholarPubMed
Gargus, JJ (2006). Ion channel functional candidate genes in multigenic neuropsychiatric disease. Biological Psychiatry 60, 177–185.CrossRefGoogle ScholarPubMed
Garzatrevino, ES, Overall, JE, Hollister, LE (1992). Verapamil versus lithium in acute mania. American Journal of Psychiatry 149, 121–122.Google ScholarPubMed
Gitlin, MJ, Swendsen, J, Heller, TL, Hammen, C (1995). Relapse and impairment in bipolar disorder. American Journal of Psychiatry 152, 1635–1640.Google ScholarPubMed
Judd, LL, Akiskal, HS, Schettler, PJ, Endicott, J, Maser, J, Solomon, DA, Leon, AC, Rice, JA, Keller, MB (2002). The long-term natural history of the weekly symptomatic status of bipolar I disorder. Archives of General Psychiatry 59, 530–537.CrossRefGoogle ScholarPubMed
Kato, T (2007). Molecular genetics of bipolar disorder and depression. Psychiatry and Clinical Neuroscience 61, 3–19.CrossRefGoogle ScholarPubMed
Levy, NA, Janicak, PG (2000). Calcium channel antagonists for the treatment of bipolar disorder. Bipolar Disorders 2, 108–119.CrossRefGoogle ScholarPubMed
Licht, RW (1998). Drug treatment of mania: a critical review. Acta Psychiatrica Scandinavica 97, 387–397.CrossRefGoogle ScholarPubMed
McGuffin, P, Rijsdijk, F, Andrew, M, Sham, P, Katz, R, Cardno, A (2003). The heritability of bipolar affective disorder and the genetic relationship to unipolar depression. Archives of General Psychiatry 60, 497–502.CrossRefGoogle ScholarPubMed
Mogilnicka, E, Czyrak, A, Maj, J (1988). Bay-K-8644 enhances immobility in the mouse behavioral despair test, an effect blocked by nifedipine. European Journal of Pharmacology 151, 307–311.CrossRefGoogle ScholarPubMed
Mulley, JC, Scheffer, IE, Petrou, S, Berkovic, SF (2003). Channelopathies as a genetic cause of epilepsy. Current Opinion in Neurology 16, 171–176.CrossRefGoogle ScholarPubMed
Ophoff, RA, Terwindt, GM, Vergouwe, MN, van Eijk, R, Oefner, PJ, Hoffman, SMG, Lamerdin, JE, Mohrenweiser, HW, Bulman, DE, Ferrari, M, Haan, J, Lindhout, D, van Ommen, GJB, Hofker, MH, Ferrari, MD, Frants, RR (1996). Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca2+ channel gene CACNL1A4. Cell 87, 543–552.CrossRefGoogle ScholarPubMed
Pazzaglia, PJ, Post, RM, Ketter, TA, Callahan, AM, Marangell, LB, Frye, MA, George, MS, Kimbrell, TA, Leverich, GS, Cora-Locatelli, G, Luckenbaugh, D (1998). Nimodipine monotherapy and carbamazepine augmentation in patients with refractory recurrent affective illness. Journal of Clinical Psychopharmacology 18, 404–413.CrossRefGoogle ScholarPubMed
Pazzaglia, PJ, Post, RM, Ketter, TA, George, MS, Marangell, LB (1993). Preliminary controlled trial of nimodipine in ultra-rapid cycling affective dysregulation. Psychiatry Research 49, 257–272.CrossRefGoogle ScholarPubMed
Radat, F, Swendsen, J (2005). Psychiatric comorbidity in migraine: a review. Cephalalgia 25, 165–178.CrossRefGoogle ScholarPubMed
Sheftell, FD, Atlas, SJ (2002). Migraine and psychiatric comorbidity: from theory and hypotheses to clinical application. Headache 42, 934–944.CrossRefGoogle ScholarPubMed
Silberstein, D, Goadsby, PJ (2002). Migraine: preventive treatment. Cephalalgia 22, 491–512.CrossRefGoogle ScholarPubMed
Sinnegger-Brauns, MJ, Hetzenauer, A, Huber, IG, Renstrom, E, Wietzorrek, G, Berjukov, S, Cavalli, M, Walter, D, Koschak, A, Waldschutz, R, Hering, S, Bova, S, Rorsman, P, Pongs, O, Singewald, N, Striessnig, J (2004). Isoform-specific regulation of mood behavior and pancreatic beta cell and cardiovascular function by L-type Ca2+ channels. Journal of Clinical Investigation 113, 1430–1439.CrossRefGoogle Scholar
Sklar, P, Gabriel, SB, McInnis, MG, Bennett, P, Lim, YM, Tsan, G, Schaffner, S, Kirov, G, Jones, I, Owen, M, Craddock, N, DePaulo, JR, Lander, ES (2002). Family-based association study of 76 candidate genes in bipolar disorder: BDNF is a potential risk locus. Molecular Psychiatry 7, 579–593.CrossRefGoogle ScholarPubMed
Sklar, P, Smoller, JW, Fan, J, Ferreira, MAR, Perlis, RH, Chambert, K, Nimgaonkar, VL, McQueen, MB, Faraone, SV, Kirby, A, de Bakker, PIW, Ogdie, MN, Thase, ME, Sachs, GS, Todd-Brown, K, Gabriel, SB, Sougnez, C, Gates, C, Blumenstiel, B, Defelice, M, Ardlie, KG, Franklin, J, Muir, WJ, McGhee, KA, MacIntyre, DJ, McLean, A, VanBeck, M, McQuillin, A, Bass, NJ, Robinson, M, Lawrence, J, Anjorin, A, Curtis, D, Scolnick, EM, Daly, MJ, Blackwood, DH, Gurling, HM, Purcell, SM (2008). Whole-genome association study of bipolar disorder. Molecular Psychiatry 13, 558–569.CrossRefGoogle ScholarPubMed
Triggle, D (1992). Biochemical and pharmacologic differences among calcium channel antagonists: clinical implications. In Calcium Antagonists in Clinical Medicine (ed. Epstein, M.), pp. 1–27. Hanley & Belfus: Philadelphia.Google Scholar
Wei, J, Hemmings, GP (2006). A further study of a possible locus for schizophrenia on the X chromosome. Biochemical and Biophysical Research Communications 344, 1241–1245.CrossRefGoogle ScholarPubMed
Wellcome Trust Case Control Consortium (2007). Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 447, 661–678.CrossRefGoogle Scholar